CORCEPT THERAPEUTICS INC Insider Trading Activity
Every SEC Form 4 insider transaction reported for CORCEPT THERAPEUTICS INC (CORT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are CORT insiders buying or selling?
In the last 12 months, CORCEPT THERAPEUTICS INC insiders reported 1 open-market purchase ($3.3M) and 51 sales ($101.2M) — net selling of $97.9M. Since January 2018, Trabud has recorded 237 Form 4 filings for CORT: 17 buys ($17.2M) and 220 sells ($241.2M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $3.3M by BAKER G LEONARD JR (Director) on Mar 19, 2026. SEC ↗
- The most recent open-market purchase was reported on Mar 19, 2026 (6 months ago).
Key Statistics (January 2018 – Oct 16, 2026)
Total Form 4 filings
237
SEC EDGAR
Insider filers
15
Insider buys (17)
$17.2M
Insider sells (220)
$241.2M
Insider sentiment
Net sellingNet insider flow of $224.0M in net selling since January 2018, and $97.9M in net selling over the last 12 months.
Recent CORT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | James N Wilson | Director | Sale | 10.0K | $114.81 | $1.1M | SEC ↗ |
| Oct 5, 2026 | Roberto Wandenkolk Vieira | President, Oncology | Sale | 8.3K | $116.10 | $967.4K | SEC ↗ |
| Oct 5, 2026 | Joseph Douglas Lyon | Chief Accounting & Technology Officer | Sale | 10.0K | $116.07 | $1.2M | SEC ↗ |
| Oct 5, 2026 | Sean Maduck | President, Corcept Endocrinology The power of attorney under which this form was signed is on file w | Sale | 25.0K | $116.26 | $2.9M | SEC ↗ |
| Sep 18, 2026 | Roberto Wandenkolk Vieira | President, Oncology | Sale | 296 | $100.82 | $29.8K | SEC ↗ |
| Sep 16, 2026 | Joseph Douglas Lyon | Chief Accounting & Technology Officer | Sale | 10.0K | $113.49 | $1.1M | SEC ↗ |
| Sep 16, 2026 | James N Wilson | Director | Sale | 10.0K | $110.69 | $1.1M | SEC ↗ |
| Sep 4, 2026 | Sean Maduck | President, Corcept Endocrinology The power of attorney under which this form was signed is on file w | Sale | 25.0K | $114.43 | $2.9M | SEC ↗ |
| Sep 4, 2026 | Roberto Wandenkolk Vieira | President, Oncology | Sale | 58.3K | $110.76 | $6.5M | SEC ↗ |
| Aug 28, 2026 | Kimberly Park | Director | Sale | 26.7K | $122.55 | $3.3M | SEC ↗ |
| Aug 27, 2026 | Sean Maduck | President, Corcept Endocrinology The power of attorney under which this form was signed is on file w | Sale | 31.0K | $125.58 | $3.9M | SEC ↗ |
| Aug 20, 2026 | David L Mahoney | Director | Sale | 103.6K | $118.25 | $12.3M | SEC ↗ |
| Aug 18, 2026 | Sean Maduck | President, Corcept Endocrinology The power of attorney under which this form was signed is on file w | Sale | 3.7K | $114.49 | $419.5K | SEC ↗ |
| Aug 18, 2026 | James N Wilson | Director | Sale | 10.0K | $111.43 | $1.1M | SEC ↗ |
| Aug 18, 2026 | Gary Charles Robb | Chief Business Officer | Sale | 10.0K | $116.26 | $1.2M | SEC ↗ |
| Aug 12, 2026 | Sean Maduck | President, Corcept Endocrinology The power of attorney under which this form was signed is on file w | Sale | 1.0K | $114.52 | $118.1K | SEC ↗ |
| Aug 12, 2026 | William Guyer | Chief Development Officer | Sale | 16.3K | $113.43 | $1.8M | SEC ↗ |
| Aug 6, 2026 | William Guyer | Chief Development Officer | Sale | 3.7K | $113.12 | $418.6K | SEC ↗ |
| Aug 5, 2026 | Sean Maduck | President, Corcept Endocrinology The power of attorney under which this form was signed is on file w | Sale | 20.3K | $114.70 | $2.3M | SEC ↗ |
| Aug 5, 2026 | Joseph Douglas Lyon | Chief Accounting & Technology Officer | Sale | 1.5K | $114.16 | $175.8K | SEC ↗ |
| Aug 3, 2026 | Atabak Mokari | Chief Financial Officer | Sale | 80.0K | $114.71 | $9.2M | SEC ↗ |
| Jul 17, 2026 | James N Wilson | Director | Sale | 10.0K | $88.30 | $883.0K | SEC ↗ |
| Jul 17, 2026 | Atabak Mokari | Chief Financial Officer | Sale | 40.0K | $87.71 | $3.5M | SEC ↗ |
| Jul 8, 2026 | William Guyer | Chief Development Officer | Sale | 20.0K | $93.13 | $1.9M | SEC ↗ |
| Jul 6, 2026 | Sean Maduck | President, Corcept Endocrinology The power of attorney under which this form was signed is on file w | Sale | 25.0K | $88.35 | $2.2M | SEC ↗ |
Showing the 25 most recent of 237 Form 4 filings for CORCEPT THERAPEUTICS INC.
Most active CORT insiders
- Sean Maduck45 filings
- Joseph Douglas Lyon38 filings
- Daniel N Swisher JR32 filings
- William Guyer32 filings
- Gary Charles Robb24 filings
Ask anything about CORT insider activity
Use Trabud's AI agent to query CORCEPT THERAPEUTICS INC's Form 4 history in plain English — "Show me CORT CEO purchases this year" or compare it against any other ticker.
Open the AI agentCORT insider trading FAQ
Are CORCEPT THERAPEUTICS INC insiders buying or selling?
In the last 12 months, CORCEPT THERAPEUTICS INC insiders reported 1 open-market purchase ($3.3M) and 51 sales ($101.2M) — net selling of $97.9M. Since January 2018, Trabud has recorded 237 Form 4 filings for CORT: 17 buys ($17.2M) and 220 sells ($241.2M). Over the full record that is net selling of $224.0M.
How many insiders trade CORT stock?
15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for CORCEPT THERAPEUTICS INC. The most recent filing was accepted on Oct 16, 2026.
Where does Trabud get CORT insider trading data?
All CORT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.